Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Family Medicine | Internal Medicine | Critical Care | Emergency Medicine | Neurology | Nursing | Pulmonology | Conference News

Back to Journal Articles

ACC: Combo Treatment Beneficial in Atrial Fibrillation

Last Updated: March 31, 2009.

 

Clopidogrel plus aspirin reduces major vascular events, but may increase hemorrhage risk

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In atrial fibrillation patients for whom vitamin K-antagonist therapy such as warfarin is not indicated, adding clopidogrel to aspirin reduces the risk of major vascular events but increases the risk of major hemorrhage, according to a study published online March 31 in the New England Journal of Medicine to coincide with the American College of Cardiology's 58th Annual Scientific Sessions held March 29 to 31 in Orlando, Fla.

TUESDAY, March 31 (HealthDay News) -- In atrial fibrillation patients for whom vitamin K-antagonist therapy such as warfarin is not indicated, adding clopidogrel to aspirin reduces the risk of major vascular events but increases the risk of major hemorrhage, according to a study published online March 31 in the New England Journal of Medicine to coincide with the American College of Cardiology's 58th Annual Scientific Sessions held March 29 to 31 in Orlando, Fla.

Stuart J. Connolly, M.D., of McMaster University in Hamilton, Ontario, Canada, and colleagues randomly assigned 7,554 patients to receive either daily clopidogrel at a dosage of 75 mg, or placebo, in addition to aspirin.

After a median follow-up of 3.6 years, the researchers found that the rate of major vascular events was lower in the combination group than in the aspirin-alone group (6.8 percent per year versus 7.6 percent per year, respectively). They found that the difference was primarily due to a decreased rate of stroke (2.4 percent per year versus 3.3 percent per year). But the investigators also found that the combination group had a higher rate of major bleeding (2 percent per year versus 1.3 percent per year).

"The purpose of the ACTIVE-A trial was to determine if the addition of clopidogrel to aspirin would reduce major vascular events and stroke in patients with atrial fibrillation, at an acceptable risk of increased hemorrhage," Connolly said in a statement. "If you treated 1,000 patients over the course of three years by adding clopidogrel to aspirin, you would prevent 28 strokes, 17 of which would be fatal or disabling, and you would prevent six heart attacks. This would occur at a cost of 20 major hemorrhages."

The study was supported by Sanofi-Aventis and Bristol-Myers Squibb; several study authors disclosed financial relationships with both companies.

Abstract
Full Text

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Lower Cancer Risk Seen in Multiple Sclerosis Patients Next: ACC: Pulmonary Hypertension Consensus Document Released

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.